TAKEDA PHARMACEUTICAL CO LTD
TAKEDA PHARMACEUTICAL CO LTD is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $47.70B market cap.
Most recent earnings call: Q3 FY25 on Jan 29, 2026.
17 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks TKPHF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TKPHF.
$ curl https://api.spokenalpha.com/v1/companies/TKPHFFAQ
Spoken Alpha indexes TKPHF's earnings call transcripts at https://spokenalpha.com/companies/TKPHF. Each call links to attributed speakers and parsed analyst Q&A. TAKEDA PHARMACEUTICAL CO LTD's own investor relations page is at https://www.takeda.com/investors/overview/.
TAKEDA PHARMACEUTICAL CO LTD (TKPHF) held its most recent earnings call on 2026-01-29, covering fiscal Q3 2025.
TAKEDA PHARMACEUTICAL CO LTD (TKPHF) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
Repeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $1.28 | $1.39 | -8.1% | +0.3% | -1.3% |
| Q4 FY2025 | $1.17 | $1.22 | -4.1% | +4.7% | +1.9% |
| Q3 FY2025 | $1.18 | $1.38 | -14.4% | -3.9% | -6.2% |
| Q2 FY2025 | $1.36 | $1.39 | -2.0% | +1.1% | -1.4% |
| Q1 FY2024 | $1.22 | $1.31 | -7.1% | +6.0% | +3.4% |
| Q4 FY2024 |
| $1.27 |
| $1.40 |
| -9.1% |
| +6.9% |
| +8.4% |
| Q3 FY2024 | $1.16 | $1.39 | -16.7% | +5.5% | +6.9% |
| Q2 FY2024 | $1.27 | $1.39 | -8.5% | -3.4% | -1.0% |
| Q1 FY2023 | $1.30 | $1.37 | -5.4% | -3.9% | -3.4% |
| Q4 FY2023 | $1.41 | $1.46 | -3.2% | +4.5% | +6.4% |